Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951661 | 0.87 | PARP1 (0.45) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL1262716 | 0.87 | DPP4 (0.46) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL1832511 | 0.85 | PARP1 (0.47) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL16033863 | 0.84 | PARP1 (0.47) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL9952433 | 0.82 | P2RX7 (0.42) | P2RX7DPP4 | |
| SCHEMBL16034060 | 0.82 | PARP1 (0.45) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL29330190 | 0.82 | PARP1 (0.45) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL24730853 | 0.81 | PARP1 (0.45) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL1262738 | 0.81 | DPP4 (0.49) | PARP1TNKS2PARP2ESR2ADORA1 | |
| SCHEMBL29899536 | 0.81 | PARP1 (0.47) | PARP1TNKS2PARP2ESR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011029842-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | PARP1 2756/4885TNKS2 1338/4885PARP2 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.